Home
News & Events
News
122
Results found
-
Vacancy at Utrecht University: Full Professor Drug Regulatory Science
Utrecht University is looking for a Full Professor Drug Regulatory Science (1.0 FTE) -
Meet us at the DIA Regulatory Science Forum in September
On 29 and 30 September DIA organizes the Regulatory Science Forum in Utrecht in which RSNN will participate. -
RSNN Expert Meeting - The interface between authorisation and reimbursement (HTA)
On November 28, 2019, the RSNN organized an Expert Meeting with the topic ‘The interface between authorisation and reimbursement (HTA)’. Sixteen experts from government, industry, clinical practice, universities and industry associations, discussed this theme in an informal setting. -
FIGON-DMD 2019
On the 23rd of September 2019 the RSNN hosted a session during the FIGON Dutch Medicines Days in Leiden. The session was chaired by Peter van Meer (assessor at CBG-MEB, vice-chair RSNN) and Joop van Gerven (chair of the CCMO). -
Announcement of an RSNN expert meeting ´The interface between authorisation and reimbursement/HTA’
On 28 November 2019, the RSNN will organise an ‘Expert Meeting’ on the topic ‘The interface between authorisation and reimbursement (HTA)’. -
RSNN session at FIGON Dutch Medicines Days
On the 23rd of September from 14:30 – 16:30 the RSNN will host a session on the FIGON Dutch Medicines Days (www.figondmd.nl) entitled “Innovative monitoring technology in clinical trials: feasible approaches, valuable evidence”. The session will be chaired by Peter van Meer (CBG) and Joop van Gerven (CCMO). -
RSNN Expert Meeting report - Pharmaceutical Compounding
On May 21st, 2019, the RSNN organized an ‘Expert Meeting’ on the topic of pharmaceutical compounding. As in many countries, there is a lively debate in the Netherlands on the complementary role of pharmaceutical compounding in the space of personalized medicine, drug shortages or coping with high priced medicines. -
Future of the drug label: Perspectives from a multistakeholder dialogue
Recently, the British Journal of Clinical Pharmacology published a paper by members of the RSNN on the future of the drug label. The paper is based on the 3rd RSNN Workshop ‘What’s in, What’s out, What’s relevant? – Towards a sensible label’ which was held in June 2018. -
Call for Regulatory Science abstracts @ FIGON Dutch Medicines Days 2019
Abstract submission for the FIGON Dutch Medicines Days is still open (deadline 1 August 2019). We encourage early career researchers to send in regulatory science abstracts for this meeting. Best abstracts will be selected for a poster or a short oral presentation in one the parallel sessions. -
RSNN Annual Report 2018 - Public Summary
2018 has been a year of expansion and consolidation for the RSNN. The number of RSNN members and partner organization has grown, as well as the number of participants in RSNN events. Furthermore, the RSNN has professionalized its communications by launching a new website and setting up an electronic newsletter. -
RSNN responds to EMA’s draft strategy ‘Regulatory Science to 2025’
The RSNN is very excited about the draft strategy and foresees significant contributions to innovating and improving regulatory science. -
RSNN Newsletter 7: July 2019
In the seventh edition, we look at events and publications in 2019. Scroll down for regulatory science news, reports and upcoming events. We share insights on an RSNN workshop and RSNN expert meeting, and we inform you about the FIGON DMD. -
Innovating clinical trials: a rich menu of options in which early dialogue will identify acceptable and feasible approaches
On 17 April 2019 the Regulatory Science Network Netherlands (RSNN) organized its fourth annual workshop. This edition focussed on “The future of clinical trials and evidence generation, and their use in regulatory decision making”. -
Regulation is too important to leave it to the regulators
Last month, professor Bert Leufkens published an editorial in the British Journal of Clinical Pharmacology. -
RSNN workshop report
The future of clinical trials and evidence generation, and their use in regulatory decision making